Hyperion DeFi (NASDAQ:HYPD) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded shares of Hyperion DeFi (NASDAQ:HYPD) from a hold rating to a strong sell rating in a research report sent to investors on Monday morning,Zacks.com reports.

A number of other research analysts have also weighed in on HYPD. Chardan Capital set a $7.75 price target on shares of Hyperion DeFi and gave the company a “buy” rating in a research note on Wednesday, December 24th. Cantor Fitzgerald started coverage on Hyperion DeFi in a report on Tuesday, December 16th. They set an “overweight” rating and a $4.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Hyperion DeFi presently has a consensus rating of “Hold” and an average target price of $5.88.

Hyperion DeFi Price Performance

Shares of NASDAQ HYPD opened at $3.45 on Monday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. The firm has a fifty day moving average of $3.48 and a 200 day moving average of $5.09. The firm has a market cap of $28.19 million, a PE ratio of -0.29 and a beta of 2.74. Hyperion DeFi has a one year low of $0.85 and a one year high of $17.18.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($7.76) earnings per share (EPS) for the quarter. The business had revenue of $0.50 million for the quarter. As a group, research analysts predict that Hyperion DeFi will post -41.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Hyperion DeFi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new stake in shares of Hyperion DeFi in the 4th quarter worth $38,000. Nations Financial Group Inc. IA ADV purchased a new stake in shares of Hyperion DeFi in the fourth quarter valued at about $40,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Hyperion DeFi in the fourth quarter valued at about $73,000. Formidable Asset Management LLC acquired a new stake in Hyperion DeFi during the fourth quarter worth about $83,000. Finally, State Street Corp acquired a new stake in Hyperion DeFi during the fourth quarter worth about $92,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.